FLT3 and acute myeloid leukemia: Given that everolimus in combination with midostaurin (a multi-kinase inhibitor that targets FLT3) was well tolerated in patients with AML in a phase 1 clinical study (Stone et al., 2012), our results suggest a promising treatment strategy for patients with FLT3-dependent AML.